NEW YORK (GenomeWeb) – Luminex today announced it has received a Health Canada Class 3 Device License for the xTAG CYP2D6 kit, a comprehensive in vitro diagnostic assay that analyzes a patient's cytochrome P450 2D6 (CYP2D6) genotype.                              

The test uses DNA extracted from a blood sample and runs on the Luminex 100/200 instrument. Results aid physicians in determining therapeutic strategies for patients who metabolize drugs differently because of the gene product, the firm said in a statement.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.